Clinical and Inflammatory Benefits of Nebulized Furosemide with Salbutamol–Ipratropium in COPD Exacerbations: A Randomized Controlled Trial
-
Mahdi Behi
,
Babak Gholamine
,
Mohammad Reza Masjedi
,
Alireza Eslaminejad
,
Esmaeil Idani
,
Mohsen Sadeghi
,
Akram Qanavati
,
Sayed Mehran Marashian
,
Esmaeil Mortaz
,
Atefeh Abedini
,
Mihan Pourabdollah
,
Bita Pakshad
,
Saeid Mahmoodian
Abstract
Exacerbations of chronic obstructive pulmonary disease (COPD) are a leading cause of morbidity, mortality, and healthcare burden. While standard bronchodilator therapy alleviates airway obstruction, its efficacy is often limited. This study evaluated nebulized furosemide, which has bronchodilatory and anti-inflammatory effects, as an adjunct to salbutamol–ipratropium in hospitalized COPD patients.
Ninety‑two patients with exacerbated COPD were randomly assigned to two equal groups (46 each). The intervention group received nebulized salbutamol–ipratropium plus furosemide (20 mg), and the control group received salbutamol–ipratropium, both every 8 hours for 10 minutes over 5 consecutive days. Demographic and clinical variables, pulmonary function indices (FEV1, FVC, FEV1/FVC), clinical outcomes (COPD Assessment Test (CAT), Modified Medical Research Council (mMRC)scores, and quality of life by St. George’s Respiratory Questionnaire (SGRQ)), arterial blood gases, and inflammatory biomarkers (TNF-α, IL-6, IL-8, CRP, ESR, neutrophil %, WBC) were measured before and after treatment.
Demographic characteristics and baseline indices did not differ significantly between the groups. Dyspnea and respiratory symptoms (mMRC and CAT scores) decreased significantly, while quality of life, improved markedly in the intervention group compared to the control group. Pulmonary function also showed significant enhancement, with the FEV₁/FVC ratio increasing. Arterial blood gas analysis showed higher PaO₂ and lower PaCO₂ in the intervention group. IL-6 and IL-8 decreased significantly, and no adverse events were reported.
Nebulized furosemide enhances standard therapy in COPD exacerbations, improving lung function, relieving symptoms, and reducing systemic inflammation. Its safety, accessibility, and low cost make it a promising adjunct treatment.
2. Al Wachami N, Guennouni M, Iderdar Y, Boumendil K, Arraji M, Mourajid Y, et al. Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMC Public Health. 2024;24(1):297.
3. Aslani MR, Abdollahi N, Matin S, Zakeri A, Ghobadi H. Effect of crocin of Crocus sativus L. on serum inflammatory markers (IL-6 and TNF-α) in COPD patients: A randomized, double-blind, placebo-controlled trial. Br J Nutr. 2023:1-19.
4. Banzett RB, Schwartzstein RM, Lansing RW, O'Donnell CR. Aerosol furosemide for dyspnea: High-dose controlled delivery does not improve effectiveness. Respiratory Physiology & Neurobiology. 2018;247:24-30.
5. Muscedere J, Maslove DM, Barden CJ, Weaver DF, Boyd JG, Sibley S, et al. Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19: A Phase 2 Randomized Controlled Double-Blind Study. Crit Care Explor. 2024;6(2):e1045.
6. Ghaysouri A, Basati G, Shams M, Tavan H. Efficiency of Nebulizing Furosemide in the Treatment of Chronic Pulmonary Obstructive Disease: A Systematic Review and Meta-Analysis of Clinical Trials. Tanaffos. 2020;19(4):340-9.
7. Hallowell RW, Schwartzstein R, O’Donnell CR, Sheridan A, Banzett RB. Controlled delivery of 80 mg aerosol furosemide does not achieve consistent dyspnea relief in patients. Lung. 2020;198:113-20.
8. Saba M, Davoodabadi A, Ghaffari A, Gilasi H, Haghpanah B. Combination adjunctive nebulized furosemide and salbutamol versus single agent therapy in COPD patients: a randomized controlled trial. Annals of medicine and surgery. 2020;57:85-90.
9. An J, Wang L, Chen Y, Yang D, Huang Y. Effects of postoperative nebulized furosemide and budesonide on postoperative sore throat in patients undergoing maxillofacial surgery: A randomized controlled trial. Advances in Oral and Maxillofacial Surgery. 2023;9:100377.
10. Atwi Z. Effects of inhaled furosemide on dyspnea and pulmonary function in people with COPD: A literature review. Canadian Journal of Respiratory Therapy: CJRT= Revue Canadienne de La Therapie Respiratoire: RCTR. 2022;58:170.
11. Barzegari H, Khavanin A, Delirrooyfard A, Shaabani S. Intravenous furosemide vs nebulized furosemide in patients with pulmonary edema: a randomized controlled trial. Health Science Reports. 2021;4(1):e235.
12. Wang S, Xiang Y-Y, Ellis R, Wattie J, Feng M, Inman MD, et al. Effects of furosemide on allergic asthmatic responses in mice. Clinical & Experimental Allergy. 2011;41(10):1456-67.
13. Sudo T, Hayashi F, Nishino T. Responses of tracheobronchial receptors to inhaled furosemide in anesthetized rats. Am J Respir Crit Care Med. 2000;162(3 Pt 1):971-5.
14. Murad H, Ghabrah T, Rafeeq M, Ali S. Subdiuretic dose of furosemide enhances albuterol effects in asthmatic mice rather than bumetanide. Allergol Immunopathol (Madr). 2018;46(6):585-93.
15. Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023;61(4).
16. Ragab R, Zaki A, Abdallah AE, Shehata GM, Elsayed M, Hameed AA. Enhancing lung function in COPD patients using nebulized furosemide as an adjunct therapy: a Triple-Blinded, Cross-Over RCT. 2024.
17. Raikwar N, Maiers T, Hohmann H, Ryan A, Snyder P, Harwani S. Abstract P213: Furosemide-mediated Suppression Of P38 MAPK Signaling Abrogates Cholinergic-mediated Salt Sensitive Hypertension In Young Spontaneously Hypertensive Rats. Hypertension. 2021;78(suppl_1):AP213-AP.
18. Ahmadi A, Ahrari S, Salimian J, Salehi Z, Karimi M, Emamvirdizadeh A, et al. p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics. Cell Communication and Signaling. 2023;21(1):314.
19. Abdelhady EI, Abd El-Hady HI, Badran SG, Rabie M. TNF-α versus IL-6 Genes Expression levels in Active Rheumatoid Arthritis: Clinical and Laboratory Determinants. Egypt J Immunol. 2023;30(4):1-10.
20. Hochdörfer T, Tiedje C, Stumpo DJ, Blackshear PJ, Gaestel M, Huber M. LPS-induced production of TNF-α and IL-6 in mast cells is dependent on p38 but independent of TTP. Cell Signal. 2013;25(6):1339-47.
21. D'Hellencourt CL, Diaw L, Cornillet P, Guenounou M. Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline. Int J Immunopharmacol. 1996;18(12):739-48.
22. Murad H, Ghabrah T, Rafeeq M, Ali S. Subdiuretic dose of furosemide enhances albuterol effects in asthmatic mice rather than bumetanide. Allergologia et Immunopathologia. 2018;46(6):585-93.
23. Bryniarski P, Nazimek K, Marcinkiewicz J. Captopril Combined with Furosemide or Hydrochlorothiazide Affects Macrophage Functions in Mouse Contact Hypersensitivity Response. International Journal of Molecular Sciences. 2022;23(1):74.
24. Xu J, Zeng Q, Li S, Su Q, Fan H. Inflammation mechanism and research progress of COPD. Frontiers in Immunology. 2024;Volume 15 - 2024.
25. de Moraes MR, da Costa AC, Corrêa KdS, Junqueira-Kipnis AP, Rabahi MF. Interleukin-6 and interleukin-8 blood levels’ poor association with the severity and clinical profile of ex-smokers with COPD. International journal of chronic obstructive pulmonary disease. 2014:735-43.
26. Zhang J, Bai C. The significance of serum interleukin-8 in acute exacerbations of chronic obstructive pulmonary disease. Tanaffos. 2018;17(1):13.
| Files | ||
| Issue | Articles in Press | |
| Section | Original Article(s) | |
| Keywords | ||
| Exacerbations of chronic obstructive pulmonary disease Furosemide Inflammation Ipratropium Salbutamol | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
